深度报告-20251117-国金证券-医药行业研究_GLP-1专题_产品迭代驱动市场扩容_关注靶点_剂型及联合疗法研发进展_38页_6mb

GLP-1 Market Analysis Summary

Market Growth and Key Drivers

The GLP-1 market is experiencing rapid growth, dominate by Novo Nordisk and Eli Lilly, with their 2015-2024 revenue rising from approximately $29 billion to $494 billion. Drugs like tirl peptide are driving this expansion, and current low permeability, especially in obesity (estimated at less than 1% globally), indicates significant market potential.

Product Iteration and Innovation

Drug advancements focus on improving efficacy and adherence through mechanisms like multi-target drugs (e.g., GLP-1R + GIPR/GCGR combinations) and oral formulations. Examples include tirl peptide offering significant weight loss and better safety profiles, while drugs like amylin-based therapies or RNAi approaches target reduced side effects and improved dosing frequency.

Investment Recommendations

The GLP-1 sector remains a high-priority investment opportunity due to its growth and innovation density. Focus on companies such as HRS9531 (Hengrui Medicine), mastralide (Xindabo), and others with strong research pipelines, including dual-target drugs, oral GLP-1 agonists, and metabolic broadeners, as they show promise in accelerating market expansion and achieving superior clinical outcomes.

Risk Assessment

Potential risks include delays in drug development, commercialization hurdles, likely from increased competition. Factors like side effects and patient adherence issues could slow market growth.